ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023
Hollow Crystallization COF Capsuled MOF Hybrids Depict Serum Metabolic Profiling for Precise Early Diagnosis and Risk Stratification of Acute Coronary Syndrome.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 43 citations in OpenAlex.
- Potential of Covalent Organic Framework in Pharmacy and Biomedicine: Influence of Structure on Properties and Applications.ChemMedChem · 2026Review
- Metabolic alterations and potential biomarkers in unstable angina investigated by lipidomic analysis.Frontiers in molecular biosciences · 2026Article
- Hollow CuS nanocubes enhance serum metabolic profiles for rapid diagnosis and severity grading of traumatic brain injury.Materials today. Bio · 2025Article
- Multi-modal single-cell platform for nanoparticle-enhanced time-series metabolic profiles of CD8Journal of nanobiotechnology · 2025Article
- Serum LncRNA PSMB8-AS1 as a novel biomarker for predicting acute coronary syndrome.Scientific reports · 2025Article
- Automated Diagnosis and Phenotyping of Tuberculosis Using Serum Metabolic Fingerprints.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- In Situ Construction of Hollow Coral-Like Porous S-Doped g-CAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Serum Metabolic Fingerprints Characterize Systemic Lupus Erythematosus.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Organic metal chalcogenide-assisted metabolic molecular diagnosis of central precocious puberty.Chemical science · 2023Article
- Next Generation of Mass Spectrometry Imaging: from Micrometer to Subcellular Resolution.Chemical & biomedical imaging · 2023Review
- Hollow Crystallization COF Capsuled MOF Hybrids Depict Serum Metabolic Profiling for Precise Early Diagnosis and Risk Stratification of Acute Coronary Syndrome.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Acute coronary syndrome (ACS), comprising unstable angina (UA) and acute myocardial infarction (AMI), is the leading cause of death worldwide. Currently, lacking effective strategies for classifying ACS hinders the prognosis improvement of ACS patients. Disclosing the nature of metabolic disorders holds the potential to reflect disease progress and high-throughput mass spectrometry-based metabolic analysis is a promising tool for large-scale screening. Herein, a hollow crystallization COF capsuled MOF hybrids (UiO-66@HCOF) assisted serum metabolic analysis is developed for the early diagnosis and risk stratification of ACS. UiO-66@HCOF exhibits unrivaled chemical and structural stability as well as endowing satisfying desorption/ionization efficiency in the detection of metabolites. Paired with machine learning algorithms, early diagnosis of ACS is achieved with the area under the curve (AUC) value of 0.945 for validation sets. Besides, a comprehensive ACS risk stratification method is established, and the AUC value for the discrimination of ACS from healthy controls, and AMI from UA are 0.890, and 0.928. Moreover, the AUC value of the subtyping of AMI is 0.964. Finally, the potential biomarkers exhibit high sensitivity and specificity. This study makes metabolic molecular diagnosis a reality and provided new insight into the progress of ACS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.